In contrast, astressin2-B administration did not significantly affect CRH-induced IBD-associated body weight loss, DAI score, change in colon length, and inflammation infiltration (Supplementary Fig. 1D–H). This evidence concerns the gene CRH and inflammatory bowel disease.